Search clinical trials for: Belantamab mafodotin (GSK2857916) anti-BCMA-immunoconjugate
Total 46 results
-
GlaxoSmithKlineAvailable
-
University of PennsylvaniaGlaxoSmithKlineRecruiting
-
GlaxoSmithKlineRecruitingMultiple MyelomaUnited States, Greece, Korea, Republic of, Singapore
-
GlaxoSmithKlineTerminatedRelapsed/Refractory Multiple MyelomaAustralia, Sweden, Canada
-
Roswell Park Cancer InstituteGlaxoSmithKlineRecruiting
-
GlaxoSmithKlineRecruitingMultiple MyelomaAustralia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
-
Hellenic Society of HematologyGlaxoSmithKlineActive, not recruiting
-
Universitätsklinikum Hamburg-EppendorfRecruitingMultiple Myeloma | Multiple Myeloma in RelapseGermany
-
Memorial Sloan Kettering Cancer CenterRecruiting
-
Massachusetts General HospitalSanofi; GlaxoSmithKlineNot yet recruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapsed CancerUnited States
-
PETHEMA FoundationAdknoma Health ResearchRecruitingRelapsed Multiple MyelomaSpain
-
Mayo ClinicRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
GlaxoSmithKlineActive, not recruitingMultiple MyelomaAustralia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
-
Hackensack Meridian HealthMerck Sharp & Dohme LLCWithdrawnMultiple Myeloma, RefractoryUnited States
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); GlaxoSmithKlineRecruitingPlasma Cell MyelomaUnited States
-
GlaxoSmithKlineIqvia Pty LtdActive, not recruitingMultiple MyelomaUnited States, Australia, Spain, United Kingdom, Canada
-
Wake Forest University Health SciencesGlaxoSmithKline; AmgenActive, not recruitingMultiple MyelomaUnited States
-
GlaxoSmithKlineActive, not recruiting
-
GlaxoSmithKlineRecruitingMultiple MyelomaUnited States, Australia, Italy, Japan, Poland, Spain, United Kingdom, France, Germany, Greece, Canada, China, Israel, Korea, Republic of, Brazil, Russian Federation, Czechia, New Zealand, Turkey
-
GlaxoSmithKlineRecruitingMultiple MyelomaAustralia, Germany, Italy, Spain, United States, Korea, Republic of, Canada, France, Poland, United Kingdom
-
Hellenic Society of HematologyGlaxoSmithKlineRecruitingNeoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic DiseaseGreece
-
PETHEMA FoundationGlaxoSmithKlineRecruitingMultiple MyelomaSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK PositiveUnited States
-
University of ChicagoGlaxoSmithKline; AmgenRecruitingMultiple Myeloma | Relapse Multiple MyelomaUnited States
-
Hellenic Society of HematologyGlaxoSmithKlineNot yet recruitingNeoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
-
GlaxoSmithKlineActive, not recruitingMultiple MyelomaUnited States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Not yet recruitingRefractory Multiple Myeloma | Recurrent Multiple Myeloma
-
University of Maryland, BaltimoreActive, not recruitingRelapsed/Refractory Multiple MyelomaUnited States
-
Hellenic Society of HematologyGlaxoSmithKlineRecruitingNeoplasms | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease | Neoplasm, Plasma CellGreece
-
GlaxoSmithKlineRecruitingMultiple MyelomaUnited States, Australia, France, Japan, Netherlands, Poland, Spain, Sweden, Greece, Canada, Korea, Republic of, Germany, Brazil, Israel, Mexico, Norway, Russian Federation
-
SanofiRecruitingPlasma Cell Myeloma RefractoryFrance, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico
-
Mayo ClinicCompletedPlasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22)... and other conditionsUnited States
-
Roswell Park Cancer InstitutePfizerRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Karyopharm Therapeutics IncBristol-Myers SquibbActive, not recruitingMultiple MyelomaUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Jonsson Comprehensive Cancer CenterUniversity of California, Los Angeles; Pfizer; Jazz PharmaceuticalsTerminatedAcute Myelogenous LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | High Risk Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Promyelocytic Leukemia With PML-RARAUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated CellsUnited States
-
Uma BorateRecruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingUntreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts | High Risk Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 | Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Acute Myeloid... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterPfizerCompletedAcute Myeloid LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid LeukemiaUnited States, Canada, Puerto Rico, Australia